评估细胞因子释放综合征的药物相互作用潜力,使用基于生理学的药物动力学模型:teclistamabb的案例研究
Marie-Emilie Willemin1, Shun Xin Wang Lin2, Loeckie De Zwart1
1Janssen Research & Development, Beerse, Belgium.
CPT: pharmacometrics & systems pharmacology
|June 4, 2024
概括
德克利斯塔马布治疗可能会导致细胞因子释放综合征 (CRS),影响药物代谢. 药物动力学模型显示,在CRS期间的IL-6水平可能会对某些药物暴露产生适度影响,特别是在初始剂量时.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物新陈代谢 药物新陈代谢
- 临床药理学 临床药理学
背景情况:
- 细胞因子释放综合征 (CRS) 与德克利斯塔马布治疗有关.
- 介乐-6 (IL-6) 可以抑制细胞P450 (CYP) 酶活性,可能影响药物代谢.
研究的目的:
- 为了评估IL-6血清水平在治疗中对CYP酶基质的暴露的影响.
- 为了评估与IL-6相关的药物相互作用的风险,在不同阶段的teclistamab治疗.
主要方法:
- 使用了基于生理学的药理动力学模型.
- 模拟了两个IL-6动力学概况:在MajesTEC-1研究中观察到的平均值和最大值.
- 评估了对CYP1A2,2C9,2C19,3A4和3A5.5基质的影响.
主要成果:
- 平均IL-6个人资料对CYP基质暴露的影响有限 (AUC比率为0.87-1.20).
- 最大的IL-6个人资料表明对欧美普拉,西姆瓦斯塔丁,米达佐拉姆和环素 (AUC比率1.90-2.23) 的影响微弱到中等.
- 在逐步增加剂量和CRS事件期间观察到的最高药物相互作用风险,在循环1后的影响会减弱.
结论:
- 通过IL-6介导的药物相互作用在初始teclistamab剂量和CRS期间最为显著.
- 在第一个循环后,IL-6对CYP活性的影响最小至中度.
- 药物相互作用的监测在tclistamab治疗的早期阶段至关重要.
相关概念视频
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Pharmacodynamic Models: Linear Concentration–Effect Model
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing drug...
Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).


